Status:
NOT_YET_RECRUITING
Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients
Lead Sponsor:
Bien-Willner Physicians Group PA
Collaborating Sponsors:
No One Left Alone
Carolina Blood and Cancer Care Associates
Conditions:
Advanced Cancer
Solid Tumor, Adult
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to measure and try to reduce leakage in precision medicine care in the community cancer clinic. The goal of precision medicine is to identify the best possible ...
Detailed Description
Precision Medicine in oncology requires the application of molecular diagnostic reporting to inform clinical decision making. However, its implementation has been slow and inefficient. Recent studies ...
Eligibility Criteria
Inclusion
- newly diagnosed or change in status Advanced Cancer patient (recurrent, refractory, metastatic, or high grade)
- Cancer patient for whom genomic testing (comprehensive genomic profile (CGP)) is recommended by relevant guidelines
Exclusion
- Patient does not seek additional treatment
- Patient younger than 18 years
- Treatment provided at a tertiary medical center
- CGP testing already performed and there is no change in patient cancer status
Key Trial Info
Start Date :
October 18 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 18 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06090513
Start Date
October 18 2024
End Date
October 18 2026
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Carolina Blood and Cancer Care Associates
Rock Hill, South Carolina, United States, 29732